Epilepsy

A group of experts in the care of patients with rare diseases—James F. Howard, MD; Sabrina Paganoni, MD, PhD; Darcy Kruger, MD, PhD; Veronica Hood, PhD; and Bruce Cree, MD, PhD—shared their perspectives on hot topics of treatment and management.

In recognition of Rare Disease Day, the NeurologyLive® team offered an extensive update on the state of care and treatment for a wide range of rare neurological diseases, including Kleine-Levin syndrome, amyotrophic lateral sclerosis, cerebral palsy, Lennox-Gastaut syndrome, and more.

Here's what is coming soon to NeurologyLive®.

Neurology News Network for the week ending February 26, 2022. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 25, 2022.

The Distinguished Professor Emerita at Indiana University School of Nursing spoke on what the task force discovered in a review of literature on stigma from 1985 through 2019. [WATCH TIME: 7 minutes]

The Distinguished Professor Emerita at Indiana University School of Nursing spoke on the prevalence of stigma in the field of epilepsy and how it can affect the daily life of patients. [WATCH TIME: 4 minutes]

Investigators concluded that despite the linear relation between plasma concentration and dose, monitoring of fenfluramine is clinically relevant due to its high interpatient pharmacokinetic variability.

Here's what is coming soon to NeurologyLive®.

Following the publication of 2 reviews from the International League Against Epilepsy Task Force on Stigma in Epilepsy, Joan K. Austin, PhD, RN, FAAN, spoke on the need to better understand this issue and address it in clinical practice.

Imad Najm, MD, provided commentary on the long-term efforts needed to understand the origins of neurological brain diseases and his desire to copy the success of the cardiovascular field.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 18, 2022.

Joan K. Austin, PhD, RN, FAAN, commented on this issue within the field, discussing key findings from 2 recent reviews completed by the International League Against Epilepsy Task Force on Stigma in Epilepsy.

The director of Cleveland Clinic’s Epilepsy Center discussed the currently known overlap between neurological diseases and the need to identify causative biomarkers. [WATCH TIME: 4 minutes]

With the physician deficit projected to grow larger within a decade, this global challenge has become a major focus of large organizations and medical societies.

With one-third of the 3.4 million US patients with epilepsy currently experience drug-resistant epilepsy, creating an urgent need for novel intervention strategies, such as stimulation approaches.

Here's what is coming soon to NeurologyLive®.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 11, 2022.

The director of Cleveland Clinic’s Epilepsy Center provided insight on a new 20-year initiative to uncover more about the origins of neurological diseases and how they occur prior to symptom onset. [WATCH TIME: 3 minutes]

The director of Cleveland Clinic’s Epilepsy Center discussed the new Cleveland Clinic Brain Study, which will evaluate predisease fingerprints from patients who go on to develop neurological disorders.

Here's what is coming soon to NeurologyLive®.

At the 2-year time point, more than 40% of preadolescent and approximately 55% of adolescent patients retained treatment with perampanel after initiation during routine clinical care.

Investigators concluded that the prompt was ‘well-suited’ for use in clinical care, but additional research is needed to better understand the association between PELHS-QOL-2-Medications and race.

Investigators noted that while epilepsy did not increase the risk for sleep disorders, there was a strong association identified with TSC-association neuropsychiatric disorders, necessitating early detection.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 4, 2022.